biOasis Welcomes Dr. Nancy Stagliano, Dr. Deborah Rathjen and Dr. Maha Radhakrishnan to Its Board of Directors
September 25 2017 - 8:00AM
Business Wire
Announces Voting Results for 2017 Annual
Meeting
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) today
announced the voting results from its Annual General Meeting held
on Sept. 21, 2017 in Vancouver, British Columbia. The total number
of shares represented in person or by proxy at the meeting was
17,212,451, representing 33.45% of the total issued and outstanding
biOasis shares.
All directors nominated by management were approved, including
new members Nancy Stagliano, Ph.D., Deborah Rathjen, Ph.D., and
Maha Radhakrishnan, M.D. as well as returning members Rob Hutchison
(Chairman, founder and former chief executive officer), Mark Day,
Ph.D. (CEO), Ron Erickson and Michael Hutchison, QC. Messrs.
Gubitz, Pearson and Fibiger were not nominated for re-election to
the board at the AGM. The Company wishes to thank Messrs. Gubitz,
Pearson and Fibiger for their efforts on behalf of the Company. As
previously announced, Michael Hutchison will step down from the
board in October and Rob Hutchison will retire from the company on
Dec. 31, 2017.
In addition to the new board slate, the shareholders approved
the option and restricted stock unit (RSU) plans.
Election of Directors
All seven (7) candidates nominated for election to the biOasis
Board of Directors and listed in the Company's Management
Information Circular, dated Aug. 21, 2017, were elected by a
majority of the shareholders present in person or represented by
proxy at the meeting.
Compensation Committee
Nancy Stagliano, Ph.D. (chair), Deborah Rathjen, Ph.D. and Mark
Day, Ph.D. have been appointed to the Compensation, Governance and
Nominating Committee.
Audit Committee
Deborah Rathjen, Ph.D. (chair), Mahalakshmi Radakrishnan, M.D.
and Ronald Erickson have been appointed members of the Audit
Committee.
Appointment of Auditors
biOasis also announced today that its shareholders have approved
the re-appointment of Manning Elliott LLP, Accountants and
Business Advisors as the Auditor of biOasis to hold office until
the next annual meeting of shareholders.
About biOasis
biOasis Technologies Inc. is a biopharmaceutical company focused
on overcoming the limitations of therapeutic drug delivery across
the blood-brain barrier (BBB). The delivery of therapeutics across
the BBB represents the single greatest challenge in treating
neurological disorders. The company is developing and
commercializing the xB3 platform, biOasis’ proprietary blood-brain
barrier delivery technology, to address unmet medical needs in the
treatment of central nervous system diseases and disorders. The
company maintains headquarters in Vancouver, Canada with offices in
Connecticut, United States. BiOasis trades on the OTCQB under the
symbol “BIOAF” and on the TSX Venture Exchange under the symbol
“BTI.” For more information about the company please visit
www.bioasis.ca.
Forward-Looking Statements
Certain statements in this press release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 or forward-looking information under applicable
Canadian securities legislation that may not be based on historical
fact, including without limitation statements containing the words
"believe," "may," "plan," "will," "estimate," "continue,"
"anticipate," "intend," "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual
results, events or developments, or industry results, to be
materially different from any future results, events or
developments express or implied by such forward-looking statements
or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital
requirements, risk associated with the completion of clinical
trials and obtaining regulatory approval to market our products,
the ability to protect our intellectual property, dependence on
collaborative partners and the prospects for negotiating additional
corporate collaborations or licensing arrangements and their
timing. Specifically, certain risks and uncertainties that could
cause such actual events or results expressed or implied by such
forward-looking statements and information to differ materially
from any future events or results expressed or implied by such
statements and information include, but are not limited to, the
risks and uncertainties that: products that we develop may not
succeed in preclinical or clinical trials, or future products in
our targeted corporate objectives; our future operating results are
uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing
additional corporate collaborations or licensing arrangements; we
may not be able to establish marketing and the costs of launching
our products may be greater than anticipated; we have no experience
in commercial manufacturing; we may face unknown risks related to
intellectual property matters; we face increased competition from
pharmaceutical and biotechnology companies; and other factors as
described in detail in our filings with the Canadian securities
regulatory authorities at www.sedar.com. Given these risks and
uncertainties, you are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. All
forward-looking statements and information made herein are based on
our current expectations and we undertake no obligation to revise
or update such forward-looking statements and information to
reflect subsequent events or circumstances, except as required by
law.
On Behalf of the Board of Directors
Dr. Mark Day
President & Chief Executive Officer
biOasis Technologies, Inc.
"Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.”
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170925005463/en/
biOasis Technologies IncCatherine London,
+1-917-763-2709Catherine@bioasis.us
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BiOasis Technologies (TSXV:BTI)
Historical Stock Chart
From Sep 2023 to Sep 2024